{
  "id": "cad-rads-ref-2967bb",
  "title": "CAD-RADS 2.0 Reference",
  "source": "cad-rads-ref.html",
  "blocks": [
    {
      "type": "paragraph",
      "text": "Source: saved page downloaded_articles/downloaded_articles/cad-rads.html. Advertisements and sidebars removed."
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Abstract"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Keywords"
    },
    {
      "type": "list",
      "items": [
        "Coronary artery disease",
        "Coronary CTA",
        "CAD-RADS",
        "Reporting and data system",
        "Stenosis severity",
        "Report standardization terminology",
        "Plaque burden",
        "Ischemia"
      ]
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Abbreviations"
    },
    {
      "type": "list",
      "items": [
        "CAD (Coronary Artery Disease)",
        "CAD-RADS (Coronary Artery Disease Reporting and Data System)",
        "CAC (Coronary Artery Calcium)",
        "CCTA (Coronary CT angiography)",
        "CT-FFR (Computed Tomography Fractional Flow Reserve)",
        "CTP (Computed Tomography Perfusion)",
        "HRP (High-risk plaque)",
        "ICA (Invasive Coronary Angiography)",
        "PCI (Percutaneous Coronary Intervention)",
        "SIS (Segment involvement score)"
      ]
    },
    {
      "type": "heading",
      "level": 2,
      "text": "1 Introduction"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "2 Clinical value of CAD-RADS and coronary CT angiography"
    },
    {
      "type": "image",
      "assetId": "asset_3312e21c18",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig. 1 Timeline plots of total quarterly PubMed citations resulting from the search CAD-RADS [Title/Abstract] OR CADRADS [Title/Abstract]. The date of the search was January 25, 2021. Permission received [6363.Takigami, A.K. Thondapu, V. Goiffon, R.J. ...Coronary artery disease reporting and data system (CAD-RADS) adoption: analysis of local trends in a large academic medical centerRadiol Cardiothorac Imaging. 2021; 3, e210016CrossrefScopus (6)PubMedGoogle Scholar] Radiol Cardiothorac Imaging. 2021 Jun; 3 (3): e210016."
    },
    {
      "type": "heading",
      "level": 2,
      "text": "3 CAD-RADS reporting system"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "3.1 CAD-RADS categories"
    },
    {
      "type": "image",
      "assetId": "asset_36d302c762",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig. 2 CAD-RADS 0 - No coronary stenosis. Absence of calcified and non-calcified plaque in the coronary tree. The classification P is not required for CAD-RADS 0."
    },
    {
      "type": "image",
      "assetId": "asset_172c02ffe0",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig. 3 CAD-RADS 1/P1 - Minimal coronary stenosis (1-24%). Plaque Burden - P1: Mild amount of plaque burden."
    },
    {
      "type": "image",
      "assetId": "asset_74c1ab45c4",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig. 4 CAD-RADS 2/P2 - Mild coronary stenosis (25-49%). Plaque Burden - P2: Moderate amount of plaque burden."
    },
    {
      "type": "image",
      "assetId": "asset_e012dbe164",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig. 5 CAD RADS 1/P3 - Plaque Burden - P3: Severe amount of plaque burden - SIS = 7, Extensive amount of diffuse plaque and minimal coronary stenosis."
    },
    {
      "type": "image",
      "assetId": "asset_76a1ac0695",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig. 6 CAD-RADS 4B/P4. Plaque Burden - P4: Three vessel severe coronary stenosis with extensive amount of plaque burden - CAC = 3607."
    },
    {
      "type": "image",
      "assetId": "asset_9f48bbd382",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig. 7 CAD-RADS 4A/P1. Focal non-calcified plaque in the mid LAD (yellow arrow) with 70-99% severe coronary stenosis and mild amount of focal non-calcified plaque burden (P1) (left). Invasive coronary angiography confirming 70-99% stenosis in the mid LAD (yellow arrow, right). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)"
    },
    {
      "type": "image",
      "assetId": "asset_ca32b32b3c",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig. 8 CAD-RADS 4B/P2. Three-vessel obstructive disease (>70% stenosis), including in 70-99% stenosis of the proximal RCA (left), 70-99% stenosis of the proximal LAD (middle) and 70-99% stenosis of the mid LCX (right) and moderate amount of non-calcified plaque burden (P2)."
    },
    {
      "type": "image",
      "assetId": "asset_4ae59c304c",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig. 9 CAD-RADS 4B/P3. Distal left main stenosis with circumferential calcified plaque resulting in >50% stenosis (arrow) and severe amount of plaque (P3 - Calcium Score = 640). Upper left panel: oblique longitudinal plane of the left main coronary artery. Lower left panel - cross-sectional slice of the distal left main coronary artery. Figures on the right - Invasive coronary angiography confirming focal severe stenosis in the distal left main coronary artery."
    },
    {
      "type": "image",
      "assetId": "asset_399d6417a7",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig. 10 CAD-RADS 5/P3. Two examples of 5mm thick MIPs CCTA cases coded as CAD-RADS 5. Left: Focal, non-calcified occlusion of the proximal RCA (arrow) and severe amount of plaque (P3). Right: Total occlusion of the proximal LCX (arrow) and extensive amount of plaque (P4). A small focus of orphan calcium along the distal LCX supports the diagnosis of chronic total occlusion."
    },
    {
      "type": "image",
      "assetId": "asset_b8db8a62b6",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig. 11 CAD-RADS N/P2. Motion artifacts obscuring the left main, LAD and LCX arteries, which renders these segments non-diagnostic (left) and moderate amount of plaque (P2 - Calcium Score = 247). Motion artifacts in the mid RCA (right) with calcified plaque."
    },
    {
      "type": "image",
      "assetId": "asset_8826af7029",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig. 12 CAD-RADS 3/P2/N. Motion artifact obscuring the mid RCA (left, arrow), which renders this segment non-diagnostic. There is also stenosis of the mid LAD with 50-69% luminal narrowing (right, arrow), qualifying this lesion as CAD RADS 3 and moderate amount of coronary plaque (P2). Although the mid RCA segment is non-diagnostic, the presence of suspected obstructive disease within the LAD should be coded as CAD RADS 3/P2/N. If the LAD lesion were mild (less than 50% diameter stenosis), and no other stenosis were identified, the patient would be coded as CAD RADS N."
    },
    {
      "type": "table",
      "columns": [
        "Degree of luminal diameter stenosis",
        "Terminology"
      ],
      "rows": [
        [
          "0%",
          "No visible stenosis"
        ],
        [
          "1-24%",
          "Minimal stenosis"
        ],
        [
          "25-49%",
          "Mild stenosis"
        ],
        [
          "50-69%",
          "Moderate stenosis"
        ],
        [
          "70-99%",
          "Severe stenosis"
        ],
        [
          "100%",
          "Occluded"
        ],
        [
          "Grading Scale for plaque burden:"
        ],
        [
          "Terminology",
          "Overall plaque burden"
        ],
        [
          "P1",
          "Mild amount of plaque"
        ],
        [
          "P2",
          "Moderate amount of plaque"
        ],
        [
          "P3",
          "Severe amount of plaque"
        ],
        [
          "P4",
          "Extensive amount of plaque"
        ],
        [
          "Grading scale for Ischemia detection:"
        ],
        [
          "Terminology",
          "Meaning"
        ],
        [
          "Modifier I",
          "Indicates that CT Ischemia test was performed either with CT-FFR or myocardial CTP"
        ],
        [
          "I+",
          "Indicates that CT-FFR or CTP demonstrates lesion-specific ischemia or reversible perfusion defect"
        ],
        [
          "I-",
          "Indicates that CT-FFR or CTP is negative for lesion specific ischemia or reversible ischemiaa"
        ],
        [
          "I +/-",
          "Indicates that CT-FFR or CTP is borderline"
        ]
      ]
    },
    {
      "type": "list",
      "items": [
        "Open table in a new tab"
      ]
    },
    {
      "type": "table",
      "columns": [
        "Overall amount of coronary plaque",
        "CAC",
        "SIS",
        "Visual"
      ],
      "rows": [
        [
          "P1",
          "Mild",
          "1-100",
          "<=2",
          "1-2 vessels with mild amount of plaque"
        ],
        [
          "P2",
          "Moderate",
          "101-300",
          "3-4",
          "1 -2 vessels with moderate amount; 3 vessels with mild amount of plaque"
        ],
        [
          "P3",
          "Severe",
          "301-999",
          "5-7",
          "3 vessels with moderate amount; 1 vessel with severe amount of plaque"
        ],
        [
          "P4",
          "Extensive",
          ">1000",
          ">=8",
          "2-3 vessels with severe amount of plaque"
        ]
      ]
    },
    {
      "type": "list",
      "items": [
        "Open table in a new tab"
      ]
    },
    {
      "type": "table",
      "columns": [],
      "rows": [
        [
          "Coronary dissection"
        ],
        [
          "Anomalous origin of the coronary arteries"
        ],
        [
          "Coronary artery aneurysm or pseudoaneurysm"
        ],
        [
          "Vasculitis"
        ],
        [
          "Coronary artery fistula"
        ],
        [
          "Extrinsic coronary artery compression"
        ],
        [
          "Arterio-venous malformation"
        ],
        [
          "Other causes"
        ]
      ]
    },
    {
      "type": "list",
      "items": [
        "Open table in a new tab"
      ]
    },
    {
      "type": "table",
      "columns": [
        "Category",
        "Degree of maximalcoronary stenosis",
        "Interpretation",
        "Further Cardiac Investigation",
        "Management considerations"
      ],
      "rows": [
        [
          "CAD-RADS 0",
          "0%(No plaque or stenosis)",
          "Absence of CADa",
          "None",
          "-Reassurance. Consider non-atherosclerotic causes of symptoms"
        ],
        [
          "CAD-RADS 1",
          "1-24%(Minimal stenosis or plaque with no stenosisb)",
          "Minimal non-obstructive CADb",
          "None",
          "-Consider non-atherosclerotic causes of symptoms-P1: Consider risk factor modification and preventive pharmacotherapy-P2: Risk factor modification and preventive pharmacotherapy-P3 or P4: Aggressive risk factor modification and preventive pharmacotherapy"
        ],
        [
          "CAD-RADS 2",
          "25-49%(Mild stenosis)",
          "Mild non-obstructive CAD",
          "None",
          "-Consider non-atherosclerotic causes of symptoms-P1 or P2: Risk factor modification and preventive pharmacotherapy-P3 or P4: Aggressive risk factor modification and preventive pharmacotherapy"
        ],
        [
          "CAD-RADS 3",
          "50-69%(Moderate stenosis)",
          "Moderate stenosis",
          "Consider functional assessmentc",
          "-P1, P2, P3 or P4: Aggressive risk factor modification and preventive pharmacotherapy-Other treatments (including anti-anginal therapy) should be considered per guideline directed cared-When modifier I+, consider ICA, especially if frequent symptoms persist after guideline-directed medical therapy"
        ],
        [
          "CAD-RADS 4",
          "A - 70-99% stenosisorB - Left main >=50% or 3- vessel obstructive (>=70%) disease",
          "Severe stenosis",
          "A: Consider ICAe or functional assessmentB: ICA is recommended",
          "P1, P2, P3 or P4: Aggressive risk factor modification and preventive pharmacotherapy.-Other treatments (including anti-anginal therapy and options of revascularization) should be considered per guideline directed carec"
        ],
        [
          "CAD-RADS 5",
          "100%(total occlusion)",
          "Total coronary occlusion or sub-total occlusion",
          "Consider ICA, functional and/or viability assessment",
          "P1, P2, P3 or P4: Aggressive risk factor modification and preventive pharmacotherapy.-Other treatments (including anti-anginal therapy and options of revascularization) should be considered per guideline directed carec"
        ],
        [
          "CAD-RADS N",
          "Non-diagnostic study",
          "Obstructive CAD cannot be excluded",
          "Additional/alternative evaluation may be needed"
        ]
      ]
    },
    {
      "type": "list",
      "items": [
        "Open table in a new tab"
      ]
    },
    {
      "type": "table",
      "columns": [
        "Category",
        "Degree of maximalcoronary stenosis",
        "Interpretation",
        "Cardiac Investigation",
        "Management considerations"
      ],
      "rows": [
        [
          "CAD-RADS 0",
          "0%",
          "ACS highly unlikely",
          "-No further evaluation of ACS is required - If Tn (+) consider other sources of increased troponin (See Table 9)",
          "-Reassurance."
        ],
        [
          "CAD-RADS 1",
          "1-24%a",
          "ACS unlikely",
          "-No further evaluation of ACS is required-If Tn (+) consider other sources of increased troponin (See Table 9)",
          "-P1 or P2: Referral for outpatient follow-up for risk factor modification and preventive pharmacotherapy.-P3 or P4: Referral for outpatient follow-up for aggressive risk factor modification and preventive pharmacotherapy"
        ],
        [
          "CAD-RADS 2",
          "25-49%",
          "ACS less likely",
          "-No further evaluation of ACS is required-If clinical suspicion of ACS is high, Tn (+) or HRP features, consider hospital admission with cardiology consultation.",
          "-P1 or P2: Referral for outpatient follow-up for risk factor modification and preventive pharmacotherapy.-P3 or P4: Referral for outpatient follow-up for aggressive risk factor modification and preventive pharmacotherapy"
        ],
        [
          "CAD-RADS 3",
          "50-69%",
          "ACS possible",
          "-Consider hospital admission with cardiology consultation.-Consider functional assessmentb",
          "-P1, P2, P3 or P4: Preventive management, including aggressive preventive pharmacotherapy. Other treatments, including anti-anginal therapies, should be considered per guideline directed carec.-When modifier I+, consider ICA."
        ],
        [
          "CAD-RADS 4",
          "A - 70-99% orB - Left main >=50% or 3-VD",
          "ACS likely",
          "-Hospital admission with cardiology consultation.AConsider ICAd or functional assessmentBICA is recommended",
          "-P1, P2, P3 or P4: Preventive management, including aggressive preventive pharmacotherapy.-Other treatments, including anti-anginal therapies and options of revascularization, should be considered per guideline directed carec"
        ],
        [
          "CAD-RADS 5",
          "100% (Total occlusion)",
          "ACS very likely",
          "-Hospital admission with cardiology consultation. Expedited ICA and revascularization if suspected acute occlusione",
          "-P1, P2, P3 or P4: Preventive management, including aggressive preventive pharmacotherapy.-Other treatments (including anti-anginal therapies and options of revascularization) should be considered per guideline directed carec"
        ],
        [
          "CAD-RADS N",
          "Non-diagnostic study",
          "ACS cannot be excluded",
          "Additional or alternative evaluation for ACS is needed"
        ]
      ]
    },
    {
      "type": "list",
      "items": [
        "Open table in a new tab"
      ]
    },
    {
      "type": "heading",
      "level": 4,
      "text": "3.1.1 CAD-RADS categories 3, 4 and 5 require further consideration"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "3.2 Plaque burden sub-classification"
    },
    {
      "type": "heading",
      "level": 4,
      "text": "3.2.1 Overall amount of coronary plaque (P)"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "3.3 Modifiers"
    },
    {
      "type": "heading",
      "level": 4,
      "text": "3.3.1 Modifier N - non-diagnostic study"
    },
    {
      "type": "heading",
      "level": 4,
      "text": "3.3.2 Modifier S = stent - presence of coronary stents"
    },
    {
      "type": "image",
      "assetId": "asset_a48eb45b0e",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig. 13 CAD-RADS 4A/P3/S. In-stent stenosis of the proximal LAD with significant luminal narrowing (70-99% stenosis) and severe amount of coronary plaque (P3). Grading of in-stent stenosis should follow the grading of normal coronary arteries (0% stenosis, 1-24% stenosis, 25-49% stenosis, 50-69% stenosis, 70-99% stenosis, and >99% stenosis). In this case, severe in-stent restenosis designates a CAD-RADS 4A lesion, which would be followed by category P3 for extensive plaque burden and the stent modifier S for the presence of stent."
    },
    {
      "type": "heading",
      "level": 4,
      "text": "3.3.3 Modifier G = grafts - presence of coronary bypass grafts"
    },
    {
      "type": "image",
      "assetId": "asset_360aaf093e",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig. 14 MODIFIER G. Coronary CTA demonstrating a patent left internal mammary artery to the LAD and patent saphenous vein grafts to the ramus intermedius and second obtuse marginal branch. No stenoses or luminal narrowing throughout the grafts (0% stenosis, left). Invasive coronary angiography demonstrating patent LIMA graft to the LAD (right). When evaluating coronary CTA of patients with bypass grafts, the native coronary artery segments proximal to the graft anastomoses should not be evaluated for purposes of CAD RADS coding. Only the grafts and the native coronary artery segments distal to and including the anastomosis should be evaluated for CAD RADS coding."
    },
    {
      "type": "heading",
      "level": 4,
      "text": "3.3.4 High-risk plaque (HRP) features (previously vulnerable plaque [V])"
    },
    {
      "type": "image",
      "assetId": "asset_5bd348d048",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig. 15 High-risk plaque (HRP) features on coronary CTA a) Spotty calcium, defined as punctate calcium within a plaque b) napkin ring sign, defined in a non-calcified plaque cross-sectional image by the presence of two features: a central area of low attenuation plaque that is apparently in contact with the lumen; and a ring-like peripheral rim of higher CT attenuation surrounding this central area (arrows); c) Positive remodeling, defined as the ratio of outer vessel diameter at the site of plaque divided by the average outer diameter of the proximal and distal vessel greater than 1.1, or Av/[(Ap + Ad)/2] >1.1; and d) Low attenuation plaque, defined as non-calcified plaque with internal attenuation less than 30 HU. Please note that a combination of two or more high-risk features is necessary to designate the plaque as high-risk for CAD-RADS."
    },
    {
      "type": "image",
      "assetId": "asset_02dab5d2ea",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig. 16 CAD-RADS 2/P2/HRP. Focal non-calcified plaque in the mid RCA with 25-49% diameter stenosis and overall moderate amount of total coronary plaque. The plaque demonstrates two high risk features, low attenuation (<30 HU) and positive remodeling, thus coding with the modifier HRP."
    },
    {
      "type": "heading",
      "level": 4,
      "text": "3.3.5 Modifier I = ischemia: CT-FFR or CTP"
    },
    {
      "type": "image",
      "assetId": "asset_1f327ca3f7",
      "alt": ""
    },
    {
      "type": "image",
      "assetId": "asset_a23288a2b6",
      "alt": ""
    },
    {
      "type": "image",
      "assetId": "asset_f442fadd70",
      "alt": ""
    },
    {
      "type": "table",
      "columns": [
        "CCTA (Stenosis)",
        "CT-FFR",
        "Interpretation and Considerations"
      ],
      "rows": [
        [
          "CT-FFR may be used in coronary stenosis ranging from 50 to 90% to better define if a stenosis is hemodynamically significant (particularly CAD-RADS 3 and 4A)CAD-RADS 3 - Moderate stenosisCAD-RADS 4A - Severe stenosisCAD-RADS 2 could be considered if proximal lesion and stenosis >=40%, including in the presence of high-risk plaque features",
          "Abnormal (I+) (<=0.75)",
          "CAD-RADS 3 or 4/I + Anatomical stenosis in one vessel with concordant lesion-specific abnormal CT-FFR <=0.75.Consider ICA for individuals likely to benefit from revascularization"
        ],
        [
          "Normal (I-) (>0.80)",
          "CAD-RADS 3 or 4/I- Anatomical stenosis with lesion-specific CT-FFR >0.80. Defer invasive angiography and optimize medical therapy.Anatomical stenosis with lesion-specific CT-FFR >0.80. At least one vessel has a distal value <= 0.80, but this value does not appear to be associated with a specific stenosis. Defer invasive angiography and optimize medical therapy."
        ],
        [
          "Borderline (I+/) (0.76-0.80)",
          "CAD-RADS 3 or 4/I +/-Anatomical stenosis in one vessel with borderline, grey-zone CT-FFR 0.76-0.80.Consider invasive angiography based on symptoms, lesion location, and trans-lesional pressure loss (>.12 significant measured 1-2 cm proximal to a stenosis - CT-FFR 1-2 cm distal to the stenosis) and for individuals likely to benefit from revascularization"
        ]
      ]
    },
    {
      "type": "list",
      "items": [
        "Open table in a new tab"
      ]
    },
    {
      "type": "image",
      "assetId": "asset_6e2cebe360",
      "alt": ""
    },
    {
      "type": "image",
      "assetId": "asset_349725330c",
      "alt": ""
    },
    {
      "type": "image",
      "assetId": "asset_6e2cebe360",
      "alt": ""
    },
    {
      "type": "image",
      "assetId": "asset_6e2cebe360",
      "alt": ""
    },
    {
      "type": "image",
      "assetId": "asset_6e2cebe360",
      "alt": ""
    },
    {
      "type": "image",
      "assetId": "asset_5ba8d25e4f",
      "alt": ""
    },
    {
      "type": "table",
      "columns": [
        "CCTA (Stenosis)",
        "Stress CTP",
        "Rest CTP",
        "Interpretation"
      ],
      "rows": [
        [
          "Stress CTP may be used in coronary stenosis ranging from 50 to 90% to better define if a stenosis is hemodynamically significant (particularly CAD-RADS 3 and 4A)CAD-RADS 3 - Moderate stenosisCAD-RADS 4A - Severe stenosisCAD-RADS 2 could be considered if proximal lesion and stenosis >40%, including in the presence of high-risk plaque features",
          "Perfusion defect (+)",
          "Negative ()",
          "Myocardial ischemia in a defined coronary territoryCAD-RADS 3 or 4/I+"
        ],
        [
          "Perfusion defect (+)",
          "Perfusion defect (+)",
          "Myocardial infarct or no evidence of ischemia in a defined coronary territoryCAD-RADS 3 or 4/I-"
        ],
        [
          "Perfusion defect (+)",
          "Perfusion defect (+)",
          "Peri-infarct ischemia in a defined coronary territoryCAD-RADS 3 or 4/I+"
        ]
      ]
    },
    {
      "type": "list",
      "items": [
        "Open table in a new tab"
      ]
    },
    {
      "type": "heading",
      "level": 4,
      "text": "3.3.6 Modifier E = exceptions"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "3.4 Presence of other cardiac or extra-cardiac findings"
    },
    {
      "type": "image",
      "assetId": "asset_2b2aa1a313",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig. 17 CAD-RADS 3/P3/HRP/S. Example demonstrating a patent stent (S) in the proximal RCA (0% stenosis) with high-risk plaque (HRP) in the proximal LAD with thick MIP images resulting in 50-69% stenosis and overall severe amount of total coronary plaque burden (P3). In isolation, the proximal LAD lesion would be coded CAD RADS 3/P3/HRP. However, since CAD RADS is coded on a per-patient basis, and a RCA stent is present, this patient would be coded as CAD RADS 3/P3/S/HRP."
    },
    {
      "type": "image",
      "assetId": "asset_c2cce1cc5f",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig. 18 Sample standardized reporting template for Coronary CTA incorporating CAD-RADS coding."
    },
    {
      "type": "table",
      "columns": [
        "2016 CAD-RADS",
        "2022 CAD-RADS"
      ],
      "rows": [
        [
          "Stenosis grading",
          "CAD-RADS 0, 1, 2, 3, 4A, 4B and 5",
          "No change"
        ],
        [
          "Plaque burden grading",
          "No systematic classification",
          "New CAD-RADS category grading scale for Plaque Burdenranging from P1 to P4"
        ],
        [
          "Modifiers",
          "Four modifiers were introduced to complement the CAD-RADS classificationFirst: modifier N (non-diagnostic)Second: modifier S (stent)Third: modifier G (graft)Fourth: modifier V (vulnerability)",
          "Addition of two new modifiers: modifier I (ischemia) and modifier E (exceptions) and replacement of modifier V (vulnerable) with HRP (high-risk plaque)First: modifier N (non-diagnostic)Second: modifier HRP (replaces V)Third: modifier I+ (ischemia), I- and I +/-Fourth: modifier S (stent)Fifth: modifier G (graft)Sixth: modifier E (exceptions)"
        ]
      ]
    },
    {
      "type": "list",
      "items": [
        "Open table in a new tab"
      ]
    },
    {
      "type": "table",
      "columns": [],
      "rows": [
        [
          "Cardiac",
          "Myocardial infarction"
        ],
        [
          "Myocardial injury"
        ],
        [
          "Myocarditis/myocardial inflammation"
        ],
        [
          "Infiltrative heart disease (amyloid, sarcoidosis)"
        ],
        [
          "Cardiomyopathy (e.g. stress cardiomyopathy)"
        ],
        [
          "Recent ablation/defibrillation"
        ],
        [
          "Vascular",
          "Pulmonary embolism/pulmonary hypertension"
        ],
        [
          "Aortic dissection"
        ],
        [
          "Other",
          "Central nervous system pathology (e.g. stroke, seizure)"
        ],
        [
          "Kidney disease"
        ],
        [
          "Chest wall trauma"
        ],
        [
          "Rhabdomyolysis/myositis"
        ],
        [
          "Chemotherapy"
        ],
        [
          "Metastatic disease"
        ],
        [
          "Inherited conditions (e.g. muscular dystrophy)"
        ],
        [
          "Carbon monoxide"
        ],
        [
          "Infectious"
        ]
      ]
    },
    {
      "type": "list",
      "items": [
        "Open table in a new tab"
      ]
    },
    {
      "type": "table",
      "columns": [
        "Stenosis",
        "Plaque",
        "Suggested Recommendation for Report"
      ],
      "rows": [
        [
          "CAD RADS 0",
          "N/A",
          "-Reassurance. Consider non-atherosclerotic causes of symptoms."
        ],
        [
          "CAD RADS 1 or CAD RADS 2",
          "P1",
          "-Consider non-atherosclerotic causes of symptoms.-Consider risk factor modification and preventive pharmacotherapy."
        ],
        [
          "P2",
          "-Consider non-atherosclerotic causes of symptoms.-Risk factor modification and preventive pharmacotherapy."
        ],
        [
          "P3 or P4",
          "-Consider non-atherosclerotic causes of symptoms.-Aggressive risk factor modification and preventive pharmacotherapy."
        ],
        [
          "CAD RADS 3",
          "P1/P2/P3/P4",
          "-Consider CT-FFR, CTP or stress testing-Aggressive risk factor modification and preventive pharmacotherapy.-Other treatments (including anti-anginal therapy) should be considered per guideline directed care"
        ],
        [
          "If I+",
          "-Consider ICA, especially if frequent symptoms persist after guideline-directed medical therapy"
        ],
        [
          "CAD RADS 4",
          "P1/P2/P3/P4",
          "-Consider ICAa or functionalb assessment-Aggressive risk factor modification and preventive pharmacotherapy.-Other treatments (including anti-anginal therapy and options of revascularization) should be considered per guideline directed care"
        ],
        [
          "CAD RADS 5",
          "P1/P2/P3/P4",
          "-Consider ICAa, functionalb, and/or viability assessment-Aggressive risk factor modification and preventive pharmacotherapy.-Other treatments (including anti-anginal therapy and options of revascularization) should be considered per guideline directed care"
        ]
      ]
    },
    {
      "type": "list",
      "items": [
        "Open table in a new tab"
      ]
    },
    {
      "type": "table",
      "columns": [
        "Stenosis",
        "Plaque",
        "Suggested Recommendation for Report"
      ],
      "rows": [
        [
          "CAD RADS 0",
          "N/A",
          "-Reassurance. No further evaluation of ACS is required.-If Tn (+) consider other sources of increased troponin"
        ],
        [
          "CAD RADS 1",
          "P1 or P2",
          "-No further evaluation of ACS is required.-If Tn (+) consider other sources of increased troponin-Referral for outpatient follow-up for risk factor modification and preventive pharmacotherapy."
        ],
        [
          "CAD RADS 1",
          "P3 or P4",
          "-No further evaluation of ACS is required.-If Tn (+) consider other sources of increased troponin-Referral for outpatient follow-up for aggressive risk factor modification and preventive pharmacotherapy."
        ],
        [
          "CAD RADS 2",
          "P1 or P2",
          "-If clinical suspicion of ACS is high, Tn (+) or high risk plaque (HRP) features, consider hospital admission with cardiology consultation.-If Tn (+) consider other sources of increased troponin-Referral for outpatient follow-up for risk factor modification and preventive pharmacotherapy,"
        ],
        [
          "CAD RADS 2",
          "P3 or P4",
          "-If clinical suspicion of ACS is high, Tn (+) or high risk plaque (HRP) features, consider hospital admission with cardiology consultation.-If Tn (+) consider other sources of increased troponin.-Referral for outpatient follow-up for aggressive risk factor modification and preventive pharmacotherapy."
        ],
        [
          "CAD RADS 3",
          "P1/P2/P3/P4",
          "-Consider hospital admission with cardiology consultation.-Consider CT-FFR, CTP or stress testing-Preventive management, including aggressive preventive pharmacotherapy. Other treatments (including anti-anginal therapy) should be considered per guideline directed care."
        ],
        [
          "If I+",
          "-Consider ICA"
        ],
        [
          "CAD RADS 4A",
          "P1/P2/P3/P4",
          "-Hospital admission with cardiology consultation.-Consider ICAa or functional assessmentb-Preventive management, including aggressive preventive pharmacotherapy. Other treatments(including anti-anginal therapy and options of revascularization) should be considered per guideline directed care"
        ],
        [
          "CAD RADS 4B",
          "P1/P2/P3/P4",
          "-Hospital admission with cardiology consultation.-ICA is recommended.-Preventive management, including aggressive preventive pharmacotherapy. Other treatments (including anti-anginal therapy and options of revascularization) should be considered per guideline directed care"
        ],
        [
          "CAD RADS 5",
          "P1/P2/P3/P4",
          "-Hospital admission with cardiology consultation.-Expedited ICA and revascularization if suspected acute occlusion.-Preventive management, including aggressive preventive pharmacotherapy. Other treatments (including anti-anginal therapy and options of revascularization) should be considered per guideline directed care."
        ]
      ]
    },
    {
      "type": "list",
      "items": [
        "Open table in a new tab"
      ]
    },
    {
      "type": "heading",
      "level": 2,
      "text": "4 Discussion"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "5 Conclusion"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Declaration of competing interest"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Additional Resources"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "References"
    }
  ]
}
